AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03026452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided RFA
Description: The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
Study NCT00717561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin
Description: IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
Study NCT04392908 — intervention group
Intervention type: OTHER
Intervention: Communication memory
Description: All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
Study NCT00141544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg
Description: ESTRATEST® administered orally QD
Study NCT00141544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified estrogens 1.25 mg
Description: Esterified estrogens 1.25 mg administered orally QD
Study NCT00138853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial component
Description: Tibial component inserted at the time of surgery
Study NCT03287830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message influenza vaccine reminders
Description: Text message reminders for second dose of influenza vaccination
Study NCT00945594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
Study NCT04904991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong
Description: This study applied the Chan-Chuang qigong program, which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice, core qigong of four moves, and cool down after qigong practice.~The movements should be repeated and maintained for 10 minutes per time, 3 time a day (Yeh et al., 2006), totally 90 minutes per week, for 3 months. The guideline booklet of Chan-Chuang qigong (Chen et al., 2019; Chuang, Yeh, \& Chung, 2017) was modified and provided to the participants, which had major sections of introduction to qigong, preparation and precautions, practical procedures with description and photos, normal physical reactions from practicing core Chan-Chuang qigong, precautions of daily life, a confirmation sheet, and a checklist of qigong performance.
Study NCT03756636 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)
Description: Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)
Study NCT02168309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Labetalol
Description: Titrate up for blood pressure control
Study NCT04161963 — intervention group
Intervention type: DEVICE
Intervention: SD-OCT
Description: Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
Study NCT02168309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine
Description: Titrate up to achieve blood pressure control
Study NCT02401932 — intervention group
Intervention type: OTHER
Intervention: Hemophagocytosis
Description: Best supportive care and immunosuppressive treatments
Study NCT01433185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message
Description: Text messages sent to women before and after delivery
Study NCT00989755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fax to Quit (F2Q)
Description: Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
Study NCT00989755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fax to Quit (F2Q)
Description: Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
Study NCT04306692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: 2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).
Study NCT04306692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days.
Study NCT01008098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram (lexapro)
Description: 0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
Study NCT02642614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Study NCT04161963 — intervention group
Intervention type: DEVICE
Intervention: OCT-A
Description: swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
Study NCT01329796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
Study NCT01329796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringers Solution
Description: Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
Study NCT02337530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib
Study NCT02337530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study NCT02642614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02642614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes
Study NCT02642614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For blinding purposes
Study NCT01148823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incisions covered for 1 day
Description: Dressing was removed on the first postoperative day.
Study NCT04545736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants >=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants >= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
Study NCT01148823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incisions covered for 6 days
Description: Dressing was removed on the 6th postoperative day.
Study NCT02090660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG Localization with Spy thoracoscope localization
Study NCT00464087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
Study NCT03186222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method.
Study NCT01831544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare MVAD® System
Description: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
Study NCT03628703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive TMS
Description: Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
Study NCT03187093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: 10-20 mg once daily for 8 weeks
Study NCT03187093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20 mg once daily for 8 weeks
Study NCT03966378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape seeds extract
Description: Grape seeds extract powder
Study NCT03966378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casein-phosphopeptide/amorphous-calcium phosphate
Description: CPP-ACP paste
Study NCT02899988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study NCT02899988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03785431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with Phantom Bioresorbable Scaffold
Description: Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
Study NCT04492618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
Study NCT02352714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Nerve Block
Description: Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
Study NCT02352714 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Paracervical Block
Description: Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
Study NCT02062034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinone
Description: 400mg daily of oral ubiquinone for 24 weeks
Study NCT02337530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02337530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT02062034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined antioxidant therapy
Description: (1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
Study NCT02062034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
Study NCT00478569 — intervention group
Intervention type: DRUG
Intervention: Parathyroid Hormone (PTH) (1-84)
Description: Adherence to PTH(1-84) treatment in Usual Clinical Settings
Study NCT03562481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Buffered Lidocaine 1:100,000 Epinephrine
Description: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
Study NCT03562481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Unbuffered Lidocaine 1:100,000 Epinephrine
Description: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
Study NCT02664441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Weekly injections of active drug.
Study NCT02664441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Weekly placebo injections
Study NCT03905187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified CR
Description: Stress management involved modified cardiac rehabilitation
Study NCT03905187 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional CR
Description: Traditional cardiac rehabilitation
Study NCT03905187 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Education
Study NCT01486914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
Study NCT01486914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
Study NCT02753101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FTC-146
Description: 10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
Study NCT01640145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Whey protein intake
Study NCT01640145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Unilateral low intensity exercise
Study NCT01640145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Unilateral low intensity exercise
Study NCT03989453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chi Kung
Description: The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.
Study NCT01735682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
Study NCT01735682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
Study NCT01735682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control treatment involves exercises of the upper limbs.
Study NCT00272948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Defibrotide
Description: Defibrotide 25 mg/kg/d
Study NCT00272948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide 25 mg/kg/d
Study NCT00272948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
Study NCT01477606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year.
Study NCT01477606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2).
Study NCT01477606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)
Study NCT00710710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Description: Intravenous Infusion
Study NCT01365325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: handled echocardiography in home monitoring program
Description: home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
Study NCT00272948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Defibrotide
Description: Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
Study NCT03978962 — intervention group
Intervention type: DEVICE
Intervention: Guided Tissue Regeneration
Description: Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction.
Study NCT01365325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ecg and clinical evaluation in home monitoring program
Description: home monitoring with clinical evaluations and ECG every three months
Study NCT03045328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.
Study NCT03045328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
Study NCT04359732 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hybrid PET/MRI
Description: An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
Study NCT03292939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: A complete Doppler ﬂow assessment of the maternal and fetal circulation
Description: A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
Study NCT02165956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Infant Cereal
Description: New Infant Cereal
Study NCT02165956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant Cereal
Description: Standard Infant Cereal
Study NCT02973542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
Study NCT02973542 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
Study NCT04052438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.
Study NCT04553653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: checklist
Description: The checklist will be implemented and healthcare providers use the checklist to manage the patients.
Study NCT00280800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: constant CPAP devices
Description: different CPAP mode
Study NCT00280800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automatic CPAP devices
Description: different CPAP mode